Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Delivery
Four million dollar milestone payment made for nasal calcitonin osteoporosis therapy
October 23rd, 2005
Unigene Laboratories, Inc. (UGNE) has received a $4 million milestone payment from Upsher-Smith Laboratories, Inc. for receiving U.S. Food and Drug Administration (FDA) approval for Fortical, its nasal calcitonin product for the treatment of postmenopausal osteoporosis. This is the final milestone payment in Unigene's exclusive U.S. licensing agreement with Upsher-Smith. Fortical, Unigene's first U.S. product, was approved and launched last month and is currently available by prescription at retail pharmacies nationwide. Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs....
Source: Medical Letter on the CDC & FDA (2005-10-23)
|
